ClinicalTrials.gg
CompletedNCT04551963Updated Oct 26, 2024Results posted

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

A Phase 1 interventional study of Zanubrutinib and Fluconazole in B-cell Malignancies, sponsored by BeiGene. Completed at 7 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study was to assess the steady-state zanubrutinib pharmacokinetics (PK) when co-administered with moderate and strong cytochrome P450 family 3 subfamily A (CYP3A) inhibitors.

02

Conditions studied

  • B-cell Malignancies
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. or cytologically confirmed CLL/SLL, MCL, WM, or MZL.
  2. disease after at least 1 . Participants with MZL are required to have failed an anti-CD20 monoclonal antibody-containing chemotherapy regimen.
  3. Baseline performance status of 0 to 1.
  4. Meet protocol guidelines for adequate bone marrow, kidney, liver, and cardiac function.

Key Exclusion Criteria:

  1. Requirement of chronic treatment with strong and moderate inhibitors or inducers or with drugs that are not allowed to be used in combination with diltiazem, clarithromycin, fluconazole, or voriconazole.
  2. History of stroke or intracranial hemorrhage (within 6 months of treatment start).
  3. Known or to zanubrutinib, diltiazem, clarithromycin, fluconazole, or voriconazole.
  4. Prior exposure to zanubrutinib or other Bruton tyrosine kinase inhibitor
  5. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Arm A: Zanubrutinib with or without Moderate CYP3A

    Cycle 1 (30 days): Participants were administered zanubrutinib at a dose of 320 mg once a day from Day 1 to Day 3; From Day 4 to Day 10, fluconazole was administered once a day at a dose of 400 mg with zanubrutinib at a reduced dose of 80 mg twice a day; On Day 11 and Day 12, zanubrutinib monotherapy was administered at 80 mg twice a day, followed by 320 mg once a day from Day 13 to Day 21; From Day 22 to Day 28, diltiazem was administered once a day at a dose of 180 mg with 80 mg zanubrutinib twice a day; On Day 29 and Day 30, zanubrutinib monotherapy was administered 80 mg twice a day. Cycles 2 to 6 (28 days each cycle): Zanubrutinib 160 mg twice a day or 320 mg once a day.

    Drug: Zanubrutinib · Drug: Fluconazole · Drug: Diltiazem

  • Experimental
    Arm B: Zanubrutinib with or without Strong CYP3A

    Cycle 1 (30 days): Participants were administered zanubrutinib at a dose of 320 mg once a day from Day 1 to Day 3; From Day 4 to Day 10, voriconazole was administered twice a day at a dose of 200 mg (total daily dose of 400 mg) with zanubrutinib at a reduced dose of 80 mg once a day; On Day 11 and Day 12, zanubrutinib monotherapy was administered at 80 mg once a day, followed by 320 mg once a day from Day 13 to Day 21; From Day 22 to Day 28, clarithromycin was administered twice a day at a dose of 250 mg (total daily dose of 500 mg) with 80 mg zanubrutinib once a day; On Day 29 and Day 30, zanubrutinib monotherapy was administered 80 mg once a day. Cycles 2 to 6 (28 days each cycle): Zanubrutinib 160 mg twice a day or 320 mg once a day.

    Drug: Zanubrutinib · Drug: Voriconazole · Drug: Clarithromycin

Interventions

  • Capsules administered at a dose and frequency as specified in the treatment arm

    Also known as: BGB-3111, BRUKINSA

  • DrugFluconazole

    Capsules administered at a dose and frequency as specified in the treatment arm

  • DrugDiltiazem

    Capsules administered at a dose and frequency as specified in the treatment arm

  • DrugVoriconazole

    Capsules administered at a dose and frequency as specified in the treatment arm

  • DrugClarithromycin

    Capsules administered at a dose and frequency as specified in the treatment arm

06

What researchers measure

Primary outcomes

  1. Arm A: Area Under Plasma Concentration-time Curve up to the Last Measurable Concentration (AUC0-t)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)

  2. Arm B: Area Under Plasma Concentration-time Curve up to the Last Measurable Concentration (AUC0-t)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)

  3. Arm A: Area Under Plasma Concentration-time Curve From Time 0 Extrapolated to 24 Hours (AUC0-24h)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)

  4. Arm B: Area Under Plasma Concentration-time Curve From Time 0 Extrapolated to 24 Hours (AUC0-24h)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)

  5. Arm A: Maximum Observed Concentration (Cmax)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)

  6. Arm B: Maximum Observed Concentration (Cmax)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)

  7. Arm A: Time of the Maximum Observed Concentration (Tmax)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)

  8. Arm B: Time of the Maximum Observed Concentration (Tmax)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)

  9. Arm A: Apparent Terminal Elimination Half-life (t1/2)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)

  10. Arm B: Apparent Terminal Elimination Half-life (t1/2)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)

Secondary outcomes

  1. Number of Participants Experiencing Adverse Events (AEs)

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinical laboratory tests

    Time frame: From the date of first study drug administration to 30 days after last dose (up to approximately 15 months)

07

Results

Posted Nov 27, 2023

Participant flow

This study was conducted at 7 study centers in Australia.

Participant flow — Overall Study
MilestoneArm A: Zanubrutinib With or Without Moderate CYP3AArm B: Zanubrutinib With or Without Strong CYP3A
Started1313
Completed1112
Not completed21
Withdrew: Physician decision11
Withdrew: Death10

Outcome measures

PrimaryArm A: Area Under Plasma Concentration-time Curve up to the Last Measurable Concentration (AUC0-t)
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Reported as:
Geometric mean · h*ng/mL
Arm A: Area Under Plasma Concentration-time Curve up to the Last Measurable Concentration (AUC0-t)
h*ng/mLArm A: Zanubrutinib With or Without Moderate CYP3A
Zanubrutinib 320 mg QD1899.32 ± 44.95
Zanubrutinib 80 mg BID + 400 mg fluconazole QD921.63 ± 45.80
Zanubrutinib 80 mg BID + 180 mg diltiazem QD797.87 ± 43.05
Statistical analysis
  • Arm A: Zanubrutinib With or Without Moderate CYP3A · Ratio of geometric least squares mean: 0.49 · 90% CI 0.42 to 0.56
  • Arm A: Zanubrutinib With or Without Moderate CYP3A · Ratio of geometric least squares mean: 0.42 · 90% CI 0.34 to 0.51
PrimaryArm B: Area Under Plasma Concentration-time Curve up to the Last Measurable Concentration (AUC0-t)
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Reported as:
Geometric mean · h*ng/mL
Arm B: Area Under Plasma Concentration-time Curve up to the Last Measurable Concentration (AUC0-t)
h*ng/mLArm B: Zanubrutinib With or Without Strong CYP3A
Zanubrutinib 320 mg QD1550.40 ± 49.20
Zanubrutinib 80 mg QD + 200 mg voriconazole BID1254.29 ± 22.36
Zanubrutinib 80 mg QD + 250 mg clarithromycin BID763.00 ± 54.79
Statistical analysis
  • Arm B: Zanubrutinib With or Without Strong CYP3A · Ratio of geometric least squares mean: 0.81 · 90% CI 0.66 to 0.99
  • Arm B: Zanubrutinib With or Without Strong CYP3A · Ratio of geometric least squares mean: 0.49 · 90% CI 0.41 to 0.58
PrimaryArm A: Area Under Plasma Concentration-time Curve From Time 0 Extrapolated to 24 Hours (AUC0-24h)
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Reported as:
Geometric mean · h*ng/mL
Arm A: Area Under Plasma Concentration-time Curve From Time 0 Extrapolated to 24 Hours (AUC0-24h)
h*ng/mLArm A: Zanubrutinib With or Without Moderate CYP3A
Zanubrutinib 320 mg QD2035.32 ± 46.97
Zanubrutinib 80 mg BID + 400 mg fluconazole QD1911.93 ± 46.97
Zanubrutinib 80 mg BID + 180 mg diltiazem QD1653.07 ± 44.88
Statistical analysis
  • Arm A: Zanubrutinib With or Without Moderate CYP3A · Ratio of geometric least squares mean: 0.94 · 90% CI 0.82 to 1.08
  • Arm A: Zanubrutinib With or Without Moderate CYP3A · Ratio of geometric least squares mean: 0.81 · 90% CI 0.66 to 0.99
PrimaryArm B: Area Under Plasma Concentration-time Curve From Time 0 Extrapolated to 24 Hours (AUC0-24h)
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Reported as:
Geometric mean · h*ng/mL
Arm B: Area Under Plasma Concentration-time Curve From Time 0 Extrapolated to 24 Hours (AUC0-24h)
h*ng/mLArm B: Zanubrutinib With or Without Strong CYP3A
Zanubrutinib 320 mg QD1578.12 ± 49.53
Zanubrutinib 80 mg QD + 200 mg voriconazole BID1376.02 ± 25.09
Zanubrutinib 80 mg QD + 250 mg clarithromycin BID766.71 ± 60.44
Statistical analysis
  • Arm B: Zanubrutinib With or Without Strong CYP3A · Ratio of geometric least squares mean: 0.83 · 90% CI 0.65 to 1.06
  • Arm B: Zanubrutinib With or Without Strong CYP3A · Ratio of geometric least squares mean: 0.48 · 90% CI 0.40 to 0.58
PrimaryArm A: Maximum Observed Concentration (Cmax)
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Reported as:
Geometric mean · ng/mL
Arm A: Maximum Observed Concentration (Cmax)
ng/mLArm A: Zanubrutinib With or Without Moderate CYP3A
Zanubrutinib 320 mg QD520.78 ± 39.18
Zanubrutinib 80 mg BID + 400 mg fluconazole QD235.72 ± 42.53
Zanubrutinib 80 mg BID + 180 mg diltiazem QD211.06 ± 36.59
Statistical analysis
  • Arm A: Zanubrutinib With or Without Moderate CYP3A · Ratio of geometric least squares mean: 0.45 · 90% CI 0.35 to 0.58
  • Arm A: Zanubrutinib With or Without Moderate CYP3A · Ratio of geometric least squares mean: 0.41 · 90% CI 0.32 to 0.51
PrimaryArm B: Maximum Observed Concentration (Cmax)
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Reported as:
Geometric mean · ng/mL
Arm B: Maximum Observed Concentration (Cmax)
ng/mLArm B: Zanubrutinib With or Without Strong CYP3A
Zanubrutinib 320 mg QD428.88 ± 43.56
Zanubrutinib 80 mg QD + 200 mg voriconazole BID353.11 ± 30.23
Zanubrutinib 80 mg QD + 250 mg clarithromycin BID215.15 ± 51.79
Statistical analysis
  • Arm B: Zanubrutinib With or Without Strong CYP3A · Ratio of geometric least squares mean: 0.82 · 90% CI 0.68 to 1.00
  • Arm B: Zanubrutinib With or Without Strong CYP3A · Ratio of geometric least squares mean: 0.50 · 90% CI 0.39 to 0.64
PrimaryArm A: Time of the Maximum Observed Concentration (Tmax)
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Reported as:
Median · Hours
Arm A: Time of the Maximum Observed Concentration (Tmax)
HoursArm A: Zanubrutinib With or Without Moderate CYP3A
Zanubrutinib 320 mg QD2.03 (1.0 to 4.0)
Zanubrutinib 80 mg BID + 400 mg fluconazole QD2.93 (1.0 to 4.0)
Zanubrutinib 80 mg BID + 180 mg diltiazem QD2.05 (1.0 to 4.2)
PrimaryArm B: Time of the Maximum Observed Concentration (Tmax)
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Reported as:
Median · Hours
Arm B: Time of the Maximum Observed Concentration (Tmax)
HoursArm B: Zanubrutinib With or Without Strong CYP3A
Zanubrutinib 320 mg QD3.00 (1.0 to 4.0)
Zanubrutinib 80 mg QD + 200 mg voriconazole BID2.05 (1.0 to 3.9)
Zanubrutinib 80 mg QD + 250 mg clarithromycin BID2.08 (0.5 to 7.9)
PrimaryArm A: Apparent Terminal Elimination Half-life (t1/2)
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Reported as:
Geometric mean · Hours
Arm A: Apparent Terminal Elimination Half-life (t1/2)
HoursArm A: Zanubrutinib With or Without Moderate CYP3A
Zanubrutinib 320 mg QD2.15 (1.4 to 4.5)
Zanubrutinib 80 mg BID + 400 mg fluconazole QD2.10 (1.7 to 3.3)
Zanubrutinib 80 mg BID + 180 mg diltiazem QD2.14 (1.4 to 4.0)
PrimaryArm B: Apparent Terminal Elimination Half-life (t1/2)
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
Reported as:
Geometric mean · Hours
Arm B: Apparent Terminal Elimination Half-life (t1/2)
HoursArm B: Zanubrutinib With or Without Strong CYP3A
Zanubrutinib 320 mg QD1.79 (1.2 to 2.5)
Zanubrutinib 80 mg QD + 200 mg voriconazole BID2.38 (1.6 to 2.8)
Zanubrutinib 80 mg QD + 250 mg clarithromycin BID2.08 (1.4 to 2.9)
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinical laboratory tests

Time frame:
From the date of first study drug administration to 30 days after last dose (up to approximately 15 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsArm A: Zanubrutinib With or Without Moderate CYP3AArm B: Zanubrutinib With or Without Strong CYP3A
At least one TEAE1212
At least one SAE31

Adverse events

Collected over From the date of first study drug administration to 30 days after last dose (up to approximately 15 months). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Zanubrutinib With or Without Moderate CYP3A1/13 (7.7%)3/13 (23.1%)12/13 (92.3%)
Arm B: Zanubrutinib With or Without Strong CYP3A0/13 (0%)1/13 (7.7%)12/13 (92.3%)
Most frequent serious events
Most frequent serious events
EventArm A: Zanubrutinib With or Without Moderate CYP3AArm B: Zanubrutinib With or Without Strong CYP3A
FallInjury, poisoning and procedural complications1/130/13
Traumatic haemorrhageInjury, poisoning and procedural complications0/131/13
Neck painMusculoskeletal and connective tissue disorders1/130/13
Mantle cell lymphoma refractoryNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/130/13
RadiculopathyNervous system disorders1/130/13
Pneumonia cryptococcalInfections and infestations1/130/13
Most frequent other events
Showing 10 of 15
Most frequent other events
EventArm A: Zanubrutinib With or Without Moderate CYP3AArm B: Zanubrutinib With or Without Strong CYP3A
ContusionInjury, poisoning and procedural complications3/134/13
ConstipationGastrointestinal disorders1/133/13
DiarrhoeaGastrointestinal disorders0/133/13
Back painMusculoskeletal and connective tissue disorders2/133/13
RashSkin and subcutaneous tissue disorders1/132/13
Abdominal pain upperGastrointestinal disorders0/132/13
FallInjury, poisoning and procedural complications1/132/13
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/132/13
Neck painMusculoskeletal and connective tissue disorders2/130/13
NeutropeniaBlood and lymphatic system disorders2/132/13

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: Zanubrutinib With or Without Moderate CYP3AArm B: Zanubrutinib With or Without Strong CYP3ATotal
Mean70.5 ± 9.8571.8 ± 8.6471.1 ± 9.10
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Zanubrutinib With or Without Moderate CYP3AArm B: Zanubrutinib With or Without Strong CYP3ATotal
Female358
Male10818
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Zanubrutinib With or Without Moderate CYP3AArm B: Zanubrutinib With or Without Strong CYP3ATotal
Hispanic or Latino000
Not Hispanic or Latino131124
Unknown or Not Reported022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Zanubrutinib With or Without Moderate CYP3AArm B: Zanubrutinib With or Without Strong CYP3ATotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American000
White111223
More than one race000
Unknown or Not Reported000
08

Study locations

7 sites
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • John Flynn Private Hospital
    Tugun, Queensland 4224, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Flinders Medical Centre
    Bedford PK, South Australia 5042, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Peninsula Private Hospital
    Frankston, Victoria 3199, Australia
  • Linear Clinical Research
    Nedlands, Western Australia 6009, Australia
09

References and documents

Publications

  • Tariq B, Ou YC, Stern JC, Mundra V, Wong Doo N, Walker P, Lewis KL, Lin C, Novotny W, Sahasranaman S, Opat S. A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies. Leuk Lymphoma. 2023 Feb;64(2):329-338. doi: 10.1080/10428194.2022.2150820. Epub 2022 Dec 8. PubMed 36480811 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Feb 2022, 15 months.

Results were first posted in Nov 2023, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2020
First posted
Sep 16, 2020
StartActual
Nov 15, 2020
Primary completionActual
Feb 21, 2022
CompletionActual
Feb 21, 2022
Results first posted
Nov 27, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04551963
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Nov 15, 2020
Primary completion
Feb 21, 2022
Completion
Feb 21, 2022
Results posted
Nov 27, 2023
Last update
Oct 26, 2024

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion